Chest
-
BronchiectasisSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: To assess the effectiveness of inhaled colistin in elderly patients with bronchiectasis and chronic bronchial PA infection in reducing hospital readmissions ⋯ The following authors have nothing to disclose: Eva Tabernero, Pilar Gil, Ramon Alkiza, Javier Garros, Anibal Hernandez, Juan Luis ArtolaNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Exacerbations are the most frequent cause of hospitalization and death among patients with COPD. Combinations of long-acting bronchodilators maximize bronchodilation and may reduce the risk of exacerbations. QVA149, a once-daily dual bronchodilator containing the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium, improves lung function, breathlessness and rescue medication use compared with twice-daily salmeterol/fluticasone combination (SFC), in patients with moderate-to-severe COPD.1METHODS: In this 26-week, multicenter, double-blind study, patients ≥ 40 years with COPD (forced expiratory volume in 1 second [FEV1] ≥40% to <80% predicted and no history of exacerbations in the previous year) were randomized (1:1) to QVA149 110/50 µg or SFC 50/500 µg. In this post hoc analysis, we report the rate of mild, moderate or severe COPD exacerbations during 26 weeks of treatment with QVA149 or SFC. ⋯ Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Prof Eric Bateman has served on advisory boards for Boehringer Ingelheim, AstraZeneca, Elevation Pharma, Napp Pharma, Novartis, Almirall, Forest, and Merck and Takeda; has served as a consultant to Navigant Consulting, IMS consulting group, ALK-Abello, Almirall, Hoffman la Roche, and ICON; has been paid lecture fees by AstraZeneca, ALK-Abello, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Nycomed/Takeda, Novartis, Pfizer, and Indegene Lifesciences Ltd. Claus Vogelmeier: Consultant fee, speaker bureau, advisory committee, etc.: AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Janssen, Novartis, Pfizer, Almirall, Takeda, and Sterna Biologicals; has been paid lecture fees by AstraZeneca, Chiesi, GlaxoSmithKline, Janssen, Talecris, Novartis, Boehringer Ingelheim, Takeda, and Pfizer. Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Congenital Disorder Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Primary ciliary dyskinesia(PCD) is a well-known congenital disorder manifesting in infancy to childhood in 70-80% cases, with the rest being diagnosed in their second decade. The ciliary dysfunction affects the upper and lower respiratory apparatus leading to recurrent sinus infections, pneumonias and irreversible processes including bronchiectasis usually before reaching adulthood. ⋯ The following authors have nothing to disclose: Prashanth Thalanayar, Fernando HolguinNo Product/Research Disclosure Information.
-
Pulmonary and Sleep MedicineSESSION TYPE: Slide PresentationPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Routine manometry has been advocated to prevent complications during therapeutic thoracentesis, but has not convincingly been shown to prevent pneumothorax ex vacuo or re-expansion pulmonary edema. As chest pain is correlated with negative pleural pressures, we aimed to determine whether the use of manometry could be associated with less pain during therapeutic thoracentesis. ⋯ The following authors have nothing to disclose: Jasleen Pannu, Zachary DePew, John Mullon, Craig Daniels, Clinton Hagen, Fabien MaldonadoNo Product/Research Disclosure Information.
-
Cardiovascular Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Cafergot is an ergotamine commonly prescribed to treat migraine headaches. As a serotonin agonist, it works at 5-HT2B receptors to cause selective vasoconstriction. In this case, a 62 YO WF who had been taking Cafergot for 15 years developed sudden onset transudative recurrent pleural effusions, all common causes ruled out by negative cytology, chemistry, culture, and cell count. She eventually developed severe multiple valvulopathy, pulmonary hypertension, and congestive hepatopathy. This case is unique in its presentation with recurrent pleural effusions of unknown etiology, with delayed diagnosis of ergotamine-induced valvulopathy given its slow progression. ⋯ The following authors have nothing to disclose: Rachel Felber, Hassan BencheqrounNo Product/Research Disclosure Information.